Bernstein Maintains a Buy on Elevance Health (ELV), Sets a $585 PT

Elevance Health, Inc. (NYSE:ELV) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 19, Bernstein analyst Lance Wilkes maintained a Buy rating on Elevance Health, Inc. (NYSE:ELV) with a price target of $585.00.

The company reported a 15.4% increase in operating revenue for fiscal Q1 2025 compared to the same period last year, reaching $48.8 billion. Adjusted operating gain for the quarter reached $3.3 billion, up 4.1% from Q1 2024.

Is Elevance Health, Inc. (ELV) The Top Falling Stock with Unusual Volume?

A medical professional working at a computer, utilizing the company’s digital solutions to improve care quality for consumers.

Elevance Health, Inc. (NYSE:ELV) reaffirmed its fiscal year 2025 adjusted diluted EPS range, expecting it to be between $34.15 and $34.85. It also returned $1.3 billion of capital to shareholders in the quarter.

Elevance Health, Inc. (NYSE:ELV) offers telehealth services to its customers, reporting in 2024 that the company conducted more than 800,000 virtual visits in 2023. This health company operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other.

The Health Benefits segment offers a range of health plans and services, while the CarelonRx segment manages pharmacy services. The Carelon Services segment offers various healthcare-related services by integrating behavioral, physical, pharmacy, and social services.

While we acknowledge the potential of ELV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XXXX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.